Cargando…
Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer
After primary treatment for prostate cancer with either radical prostatectomy or radiotherapy, a significant proportion of patients are at risk of developing metastases. In recent years, a deeper understanding of the underlying biology together with improved imaging techniques and the advent of new...
Autores principales: | Marvaso, Giulia, Volpe, Stefania, Pepa, Matteo, Zaffaroni, Mattia, Corrao, Giulia, Augugliaro, Matteo, Nolè, Franco, De Cobelli, Ottavio, Jereczek-Fossa, Barbara Alicja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747627/ https://www.ncbi.nlm.nih.gov/pubmed/35023972 http://dx.doi.org/10.2147/CMAR.S321136 |
Ejemplares similares
-
Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome
por: Riva, Giulia, et al.
Publicado: (2017) -
Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches
por: Marvaso, Giulia, et al.
Publicado: (2021) -
Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review
por: Corrao, Giulia, et al.
Publicado: (2021) -
Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies
por: Marvaso, Giulia, et al.
Publicado: (2021) -
Machine Learning-Based Models for Prediction of Toxicity Outcomes in Radiotherapy
por: Isaksson, Lars J., et al.
Publicado: (2020)